Cytek BioSciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
25.5%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$208.8Mnext fiscal year
FY EPS (est.)
-$0.03next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Full Year 2026 Financial Results | 25 Feb 2027 |
Monitoring Framework
Key Performance Indicators
Total Installed Base of Instruments Quarterly3.8K
Quarterly Revenue Quarterly44.1M
Full-Year Revenue Guidance Annually208.5MTarget: 205000000 to 212000000
Recurring Revenue Share of Total Revenue Quarterly35.0%
Watch Items
- Operating Expenses and G&A Litigation CostsTrigger: Operating expenses exceeding $40 million per quarter driven by patent litigationAction: Evaluate legal settlement options or cost-containment measures to protect operating margins.
- EMEA and APAC Instrument Demand RecoveryTrigger: Continued double-digit year-over-year declines in APAC or EMEA regional revenuesAction: Reassess distributor networks, adjust regional pricing strategies, or reallocate sales resources to high-growth U.S. sectors.
- Transition to Three Distinct Business UnitsTrigger: Delays in operational rollout beyond Q3 2026Action: Review progress of the strategic realignment into Solutions and Clinical, Research Technology, and Service business units to prevent commercial disruption.
Research as of 19 Jun 2026